Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14977315 | 1.00 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2958183 | 0.86 | CA1 (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL25448807 | 0.81 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28332424 | 0.81 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL17256626 | 0.81 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15329421 | 0.79 | CA1 (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6275732 | 0.79 | CA12 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15329419 | 0.79 | CA1 (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9763264 | 0.79 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9763269 | 0.79 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782567-B1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | UNIV CALIFORNIA (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | FOND ST ITALIANO TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-9353075-B2 | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2782567-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | The Regents of The University of California (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | disclosed |
| WO-2013078430-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | NAAA, FAAH, FAAH2 | CTSK 1468/4885CTSS 917/4885CA1 592/4885 |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | NAAA, FAAH, FAAH2 | CTSK 1468/4885CTSS 917/4885CA1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.